214 related articles for article (PubMed ID: 38383387)
1. PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
Marcazzan S; Braz Carvalho MJ; Nguyen NT; Strangmann J; Slotta-Huspenina J; Tenditnaya A; Tschurtschenthaler M; Rieder J; Proaño-Vasco A; Ntziachristos V; Steiger K; Gorpas D; Quante M; Kossatz S
J Exp Clin Cancer Res; 2024 Feb; 43(1):53. PubMed ID: 38383387
[TBL] [Abstract][Full Text] [Related]
2. Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus.
Fang HY; Stangl S; Marcazzan S; Carvalho MJB; Baumeister T; Anand A; Strangmann J; Huspenina JS; Wang TC; Schmid RM; Feith M; Friess H; Ntziachristos V; Multhoff G; Gorpas D; Quante M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2049-2063. PubMed ID: 34882260
[TBL] [Abstract][Full Text] [Related]
3. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
[TBL] [Abstract][Full Text] [Related]
4. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.
Münch NS; Fang HY; Ingermann J; Maurer HC; Anand A; Kellner V; Sahm V; Wiethaler M; Baumeister T; Wein F; Einwächter H; Bolze F; Klingenspor M; Haller D; Kavanagh M; Lysaght J; Friedman R; Dannenberg AJ; Pollak M; Holt PR; Muthupalani S; Fox JG; Whary MT; Lee Y; Ren TY; Elliot R; Fitzgerald R; Steiger K; Schmid RM; Wang TC; Quante M
Gastroenterology; 2019 Aug; 157(2):492-506.e2. PubMed ID: 30998992
[TBL] [Abstract][Full Text] [Related]
5. Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW.
Gabriëls RY; van Heijst LE; Hooghiemstra WTR; van der Waaij AM; Kats-Ugurlu G; Karrenbeld A; Robinson DJ; Tenditnaya A; Ntziachristos V; Gorpas D; Nagengast WB
J Nucl Med; 2023 May; 64(5):803-808. PubMed ID: 36604181
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
Demétrio de Souza França P; Kossatz S; Brand C; Karassawa Zanoni D; Roberts S; Guru N; Adilbay D; Mauguen A; Valero Mayor C; Weber WA; Schöder H; Ghossein RA; Ganly I; Patel SG; Reiner T
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3618-3630. PubMed ID: 33954826
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus.
Marcazzan S; Braz Carvalho MJ; Konrad M; Strangmann J; Tenditnaya A; Baumeister T; Schmid RM; Wester HJ; Ntziachristos V; Gorpas D; Wang TC; Schottelius M; Quante M
EJNMMI Res; 2022 Jan; 12(1):2. PubMed ID: 35006394
[TBL] [Abstract][Full Text] [Related]
8. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.
Kossatz S; Brand C; Gutiontov S; Liu JT; Lee NY; Gönen M; Weber WA; Reiner T
Sci Rep; 2016 Feb; 6():21371. PubMed ID: 26900125
[TBL] [Abstract][Full Text] [Related]
9. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
Streppel MM; Pai S; Campbell NR; Hu C; Yabuuchi S; Canto MI; Wang JS; Montgomery EA; Maitra A
Clin Cancer Res; 2013 Aug; 19(15):4067-78. PubMed ID: 23757351
[TBL] [Abstract][Full Text] [Related]
11. Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.
Kossatz S; Weber W; Reiner T
Mol Imaging; 2017; 16():1536012117723786. PubMed ID: 28856922
[TBL] [Abstract][Full Text] [Related]
12. High definition versus standard definition white light endoscopy for detecting dysplasia in patients with Barrett's esophagus.
Sami SS; Subramanian V; Butt WM; Bejkar G; Coleman J; Mannath J; Ragunath K
Dis Esophagus; 2015; 28(8):742-9. PubMed ID: 25209721
[TBL] [Abstract][Full Text] [Related]
13. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
[TBL] [Abstract][Full Text] [Related]
14. Detection and staging of esophageal cancers within Barrett's esophagus is improved by assessment in specialized Barrett's units.
Cameron GR; Jayasekera CS; Williams R; Macrae FA; Desmond PV; Taylor AC
Gastrointest Endosc; 2014 Dec; 80(6):971-83.e1. PubMed ID: 24929493
[TBL] [Abstract][Full Text] [Related]
15. Chromoendoscopy and magnification endoscopy for diagnosing esophageal cancer and dysplasia.
Connor MJ; Sharma P
Thorac Surg Clin; 2004 Feb; 14(1):87-94. PubMed ID: 15382312
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of PARP1 is involved in development of Barrett's esophagus.
Zhang C; Ma T; Luo T; Li A; Gao X; Wang ZG; Li F
World J Gastroenterol; 2018 Mar; 24(9):982-991. PubMed ID: 29531462
[TBL] [Abstract][Full Text] [Related]
17. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
18. Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.
Sahm V; Maurer C; Baumeister T; Anand A; Strangmann J; Schmid RM; Wang TC; Quante M
Oncotarget; 2022; 13():347-359. PubMed ID: 35178191
[TBL] [Abstract][Full Text] [Related]
19. Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening.
Konda VJ; Cherkezyan L; Subramanian H; Wroblewski K; Damania D; Becker V; Gonzalez MH; Koons A; Goldberg M; Ferguson MK; Waxman I; Roy HK; Backman V
Endoscopy; 2013 Dec; 45(12):983-8. PubMed ID: 24019132
[TBL] [Abstract][Full Text] [Related]
20. C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies.
de Jongh SJ; Voskuil FJ; Schmidt I; Karrenbeld A; Kats-Ugurlu G; Meersma GJ; Westerhof J; Witjes MJH; van Dam GM; Robinson DJ; Nagengast WB
Theranostics; 2020; 10(12):5357-5367. PubMed ID: 32373217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
